Overview Of IgA Nephropathy (IgAN)
This infographic focuses on IgA Nephropathy (IgAN). Read More
- About
- IgAN
- Events
- Resource Center
- Simulators
What interests you?+Help Us Enhance Your NephU ExperienceHelp Us Enhance Your NephU Experience
User experience form
IgA Nephropathy
Biomarkers in IgA Nephropathy
This webinar will focus on the current biomarker landscape as well as novel biomarkers that are currently being studied. The webinar will also focus on why biomarkers are needed and… Read MoreBasic Anatomy of Glomerulus & IgAN Pathology
This infographic will give an opportunity to learn more about where IgA deposits in the kidney and how the depositions impact the patient’s outcome. Read MoreIgA Nephropathy: Pathogenesis, the Role of APRIL & the 4-Hit Process, & a Patient Case Study
The goal of this event is to provide a detailed overview of the Four-Hit hypothesis as well as explain the role of APRIL in disease pathogenesis. Read MoreNavigating the Differential Diagnosis of Proteinuria with an Emphasis on IgA Nephropathy
To enhance your understanding of the presentation, differential diagnosis, and workup of proteinuria. There is also the opportunity to explore the pathophysiology and risk of progression of IgA nephropathy and… Read More4 Part IgAN Experience
During this presentation you will learn the clinical presentation, diagnosis, prognosis, and unmet treatment needs of IgAN. Read More4 Part IgAN Experience
During this presentation you will learn the clinical presentation, diagnosis, prognosis, and unmet treatment needs of IgAN. Read More4 Part IgAN Experience
During this presentation you will learn the clinical presentation, diagnosis, prognosis, and unmet treatment needs of IgAN. Read MoreThe Role of APRIL in IgA Nephropathy
Learn about the pathogenic process that causes kidney injury and about APRIL, an important initiating and sustaining driver in IgAN. Reference: Mathur M, et al. J Clin Med. 2023;12(21):6927. Read MoreRisk of Progression to Kidney Failure in IgA Nephropathy
This infographic highlights the risk of progression to ESKD, including in patients traditionally considered low risk. Read MoreNephU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI) - committed supporters of the kidney health community. The information provided through NephU is intended for the educational benefit of health care professionals and others who support care for those with kidney disease and other related conditions. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing NephU’s educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by NephU. Some of the contributors may be paid consultants of OPDC and/or OAPI.©2025 Otsuka Pharmaceutical Development & Commercialization, Inc. All rights reserved. - IgAN
